This segment focuses on the research, development, and commercialization of novel therapeutics for various cancers. Mirati's primary focus is on developing targeted therapies that address specific genetic mutations and immunological promoters of cancer. Research and development activities include preclinical studies, clinical trials, and regulatory submissions. The company utilizes advanced technologies such as small molecule inhibitors and companion diagnostics to identify and treat patients with specific genetic profiles. The lead product candidates include MRTX849 (adagrasib), a KRAS G12C inhibitor, and sitravatinib, a spectrum-selective kinase inhibitor. These therapies are being evaluated in multiple clinical trials for non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, and other cancers. The patient impact is significant, as these therapies aim to improve outcomes for patients with difficult-to-treat cancers. Mirati's market positioning is as a leader in targeted oncology, with a focus on precision medicine. The company has collaborations with other pharmaceutical companies, such as BeiGene, to expand the development and commercialization of its products. Future opportunities include expanding the use of its therapies to other cancer types and developing new drug candidates. Regulatory and clinical aspects include obtaining FDA approval for its lead product candidates and conducting clinical trials to demonstrate safety and efficacy.